Brain Scientific Inc. (BRSF) Receives FDA Clearance for Next-Gen NeuroCap
- BRSF announced it has FDA clearance for next-gen NeuroCap
- The newest version of the NeuroCap has added velcro strips, expanded size range to include pediatrics
- New device can stay on the patient’s head for up to four hours
Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company, announced it has received clearance from the FDA for its next-generation NeuroCap(TM) (https://nnw.fm/c2RZm). This device is an advanced electroencephalogram (“EEG”) electrode array used in routine clinical and research settings. Like the previous version, the newest version of the NeuroCap will help improve patient access to neurological care through its simplicity, cost efficiency and one-time use. However, the next-gen version comes with a few upgrades.
“We are constantly working on new products for the EEG market,” stated Irina Nazarova, marketing director at Brain Scientific. “In the new version of NeuroCap, we added velcro strips for better adhesion. We also expanded the size range by adding an extra-small size. And now this device is designed for broader use, in addition to intensive care units and ERs.”
The next generation of the NeuroCap includes a pediatric version. The newer version only takes five minutes to apply and can stay on a patient’s head for up to four hours. The lengthy task of head measurement and electrode placement is eliminated with pre-gelled, fixed electrode locations. The ease of use and disposability limits contact between EEG technicians and patients, a much-needed change in a post-COVID era.
However, the risk if virus existed even prior to the pandemic. In fact, the largest known outbreak of hepatitis B (“HBV”), with 14,000 cases between 1991 to 1996, was traced back to one EEG lab (https://nnw.fm/NxM2U). And that concern is well founded. The cleaning process of bulky EEG equipment is complicated. Wires can get tangled, and cleaning products expire. Microscopic debris, such as blood and pathogens, can be left behind. Good intentions and cleaning policies can only go so far in protecting patients. Improper cleaning methods come with heavy fines, and PR nightmares. The simple, cost-effective solution is to switch to single-use EEG electrode products.
BRSF’s NeuroCap offers additional benefits. Traditional EEGs require application by a skilled professional and can take up to 30 minutes to start the routine EEG test. That amount of time does not include cleaning. The NeuroCap reduces the time needed from 30 minutes to only five, and the device requires no cleaning or sterilization because the product is disposable. It eliminates both the threat and the worry.
While COVID has highlighted the need for more sanitary measures and disposable EEGs, it has also made clear the great divide in neurological care demographically. Brain Scientific is dedicated to making neurological care accessible to all.
For more information, visit the company’s website at www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://nnw.fm/BRSF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- BRSF announced it has FDA clearance for next-gen NeuroCap
- The newest version of the NeuroCap has added velcro strips, expanded size range to include pediatrics
- New device can stay on the patient’s head for up to four hours
Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company, announced it has received clearance from the FDA for its next-generation NeuroCap(TM) (https://nnw.fm/c2RZm). This device is an advanced electroencephalogram (“EEG”) electrode array used in routine clinical and research settings. Like the previous version, the newest version of the NeuroCap will help improve patient access to neurological care through its simplicity, cost efficiency and one-time use. However, the next-gen version comes with a few upgrades.
“We are constantly working on new products for the EEG market,” stated Irina Nazarova, marketing director at Brain Scientific. “In the new version of NeuroCap, we added velcro strips for better adhesion. We also expanded the size range by adding an extra-small size. And now this device is designed for broader use, in addition to intensive care units and ERs.”
The next generation of the NeuroCap includes a pediatric version. The newer version only takes five minutes to apply and can stay on a patient’s head for up to four hours. The lengthy task of head measurement and electrode placement is eliminated with pre-gelled, fixed electrode locations. The ease of use and disposability limits contact between EEG technicians and patients, a much-needed change in a post-COVID era.
However, the risk if virus existed even prior to the pandemic. In fact, the largest known outbreak of hepatitis B (“HBV”), with 14,000 cases between 1991 to 1996, was traced back to one EEG lab (https://nnw.fm/NxM2U). And that concern is well founded. The cleaning process of bulky EEG equipment is complicated. Wires can get tangled, and cleaning products expire. Microscopic debris, such as blood and pathogens, can be left behind. Good intentions and cleaning policies can only go so far in protecting patients. Improper cleaning methods come with heavy fines, and PR nightmares. The simple, cost-effective solution is to switch to single-use EEG electrode products.
BRSF’s NeuroCap offers additional benefits. Traditional EEGs require application by a skilled professional and can take up to 30 minutes to start the routine EEG test. That amount of time does not include cleaning. The NeuroCap reduces the time needed from 30 minutes to only five, and the device requires no cleaning or sterilization because the product is disposable. It eliminates both the threat and the worry.
While COVID has highlighted the need for more sanitary measures and disposable EEGs, it has also made clear the great divide in neurological care demographically. Brain Scientific is dedicated to making neurological care accessible to all.
For more information, visit the company’s website at www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://nnw.fm/BRSF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
